Cipla Limited has issued a clarification regarding media reports concerning US Food and Drug Administration (USFDA) inspectional observations in Form 483 at Pharmathen International S.A. Pharmathen is identified as a supply partner manufacturing Lanreotide Injection for Cipla USA Inc., a wholly owned subsidiary. The USFDA conducted an inspection at Pharmathen's manufacturing facility in Rodopi, Greece, from November 10, 2025, to November 21, 2025. Following this inspection, Pharmathen received nine inspectional observations. Cipla is currently evaluating the impact of these observations and will inform the stock exchanges of any material updates in accordance with regulatory requirements. The company provided this clarification in response to a communication from the stock exchanges seeking details on the media reports.
